Effects of Once-Weekly Subcutaneous Semaglutide on Coronary Artery Disease Outcomes in Patients with Type 2 Diabetes with or at High Risk for Cardiovascular Disease: Insights from the SUSTAIN-6 Trial.
Ahmed A KolkailahIldiko LingvayIdit Dobrecky-MeryAlona AharonovichJens-Peter DavidCecilie HolseSøren RasmussenDarren K McGuirePublished in: Diabetes, obesity & metabolism (2022)
Keyphrases
- coronary artery disease
- cardiovascular disease
- cardiovascular events
- phase iii
- study protocol
- clinical trial
- phase ii
- percutaneous coronary intervention
- type diabetes
- coronary artery bypass grafting
- cardiovascular risk factors
- metabolic syndrome
- open label
- heart failure
- adipose tissue
- atrial fibrillation
- aortic valve
- glycemic control
- transcatheter aortic valve replacement